Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR T790M/L858R (#RDB15494)

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, T790M and L858R, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment cDNA was obtained from A549 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction). This clone contains a cDNA fragment corresponding to the 258nt to 3890nt of NM_005228.4. Known differences (at least) : C to T substitution at 731nt (N, synonym) ; C to T substitution at 2626nt (T790M) ; T to G substitution at 2830nt (L858R).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
備考
Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15494 pENTER-EGFR T790M/L858R DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pENTER-EGFR T790M/L858R was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15494).

Reference section:

Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15494_A7K8p1-2.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 (Pr0531)
Region: attL1,insert 5'
Sequence file: RDB15494_A7K8d.seq check
>D04925A7_A7K8_2_rrnBT1ter_F2_G04_19_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNCC TTTCGTTTNN TTTGATGCCT GGCAGTTCCN TACTCTCGCG
   61 TTAACGCTAG CATGGNTGTT TTCCCAGTCA CGACGTTGTA AAACGACGGC CAGTCTTAAG
  121 CTCGGGCCCC AAATAATGAT TTTATTTTGA CTGATAGTGA CCTGTTCGTT GCAACAAATT
  181 GATGAGCAAT GCTTTTTTAT AATGCCAACT TTGTACAAAA AAGCAGGCTC CGCGGCCGCC
  241 CCCTTCACCA TGCGACCCTC CGGGACGGCC GGGGCAGCGC TCCTGGCGCT GCTGGCTGCG
  301 CTCTGCCCGG CGAGTCGGGC TCTGGAGGAA AAGAAAGTTT GCCAAGGCAC GAGTAACAAG
  361 CTCACGCAGT TGGGCACTTT TGAAGATCAT TTTCTCAGCC TCCAGAGGAT GTTCAATAAC
  421 TGTGAGGTGG TCCTTGGGAA TTTGGAAATT ACCTATGTGC AGAGGAATTA TGATCTTTCC
  481 TTCTTAAAGA CCATCCAGGA GGTGGCTGGT TATGTCCTCA TTGCCCTCAA CACAGTGGAG
  541 CGAATTCCTT TGGAAAACCT GCAGATCATC AGAGGAAATA TGTACTACGA AAATTCCTAT
  601 GCCTTAGCAG TCTTATCTAA CTATGATGCA AATAAAACCG GACTGAAGGA GCTGCCCATG
  661 AGAAATTTAC AGGAAATCCT GCATGGCGCC GTGCGGTTCA GCAACAACCC TGCCCTGTGC
  721 AATGTGGAGA GCATCCAGTG GCGGGACATA GTCAGCAGTG ACTTTCTCAG CAACATGTCG
  781 ATGGACTTCC AGAACCACCT NNGCAGCTGC CAAAAGTGTG NTCCAAGCTG TCCCNATGNN
  841 ANCTGCTGGG GTGCANGANA NGANAACTGN NAGAAACTNN NCAAAATCAT CTGNGCCCAG
  901 CAGNGCTCCN GGNGCTGCCG NNNNNANNCC NNCCANNGNN NGCNGNCNCA ACCANNGNNC
961 TNCNNNNNNN NNANGNCCCC CNGGNNANNN NNNNNNN
//
Primer: pDONR_R (Pr0071)
Region: attL2,insert 3'
Sequence file: RDB15494_A7K8e.seq check
>D04925A7_A7K8_2_pDONR_R_G05_20_ABI24.ab1
    1 NNNNNNNNNN NNNNCNNTNN NNNTGTAATA CGACTCACTA TAGGGGANAT CAGCTGGATG
   61 GCAAATAATG ATTTTATTTT GACTGATAGT GACCTGTTCG TTGCAACAAA TTGATAAGCA
  121 ATGCTTTCTT ATAATGCCAA CTTTGTACAA GAAAGCTGGG TCGGCGCGCC CACCCTTTCA
  181 TGCTCCAATA AATTCACTGC TTTGTGGCGC GACCCTTAGG TATTCTGCAT TTTCAGCTGT
  241 GGAGCCCTTA AAGATGCCAT TTGGCTTGGC TTCCTTGGGA AAGAAGTCCT GCTGGTAGTC
  301 AGGGTTGTCC AGGCTAATTT GGTGGCTGCC TTTCTGGGCC CAGTGGGCAG GGCTGTCGAA
  361 TGTGCTGTTG ACACAGGTGG GCTGGACAGT GTTGAGATAC TCGGGGTTGC CCACTGCAGT
  421 GCTGTGGGGG TCCTGGTAGT GTGGGTCTCT GCTGGGCGCG GGGTTCAGAG GCTGATTGTG
  481 ATAGACAGGA TTCTGCACAG AGCCAGCGGG CCTTTTGGGA ACGGACTGGT TTATGTATTC
  541 AGGCACTGGG AGGAAGGTGT CGTCTATGCT GTCCTCAGTC AAGGCGCCTG TGGGGTCTGA
  601 GCTGTATCGC TGCAAGAAGC TGTCTTCCTT GATGGGACAG CTTTGCAGCC CATTTCTATC
  661 AATGCAAGCC ACGGTGGAAT TGTTGCTGGT TGCACTCAGA GAGCTCANGA NGGGAGTCCG
  721 TGNCGTGGAG GGGCTGCTGA ANAAGCCCTG CTGTGGGANG ANGTACTCGT CGGCATCCAC
  781 CACGTCGTCC ATGTCTTCTT CATCCNTCAN GGCACGGTAN AANTTGGANT CTGTANGANT
  841 TGNCAAATGC ATTCTTTCNT CCCCCNNNAT GANAAGGTAN CGCNNGGGGN CTCNGGCCAT
  901 TTNNGANAAT TCNATGATCN ACTCNNNGAN NTTTGGGNNN NTATNNNCGN CNNTCNNNNN
961 NNNNN
//
Primer: EGFR-F5 (Pr0313)
Region: insert mid (T790M/L858R)
Sequence file: RDB15494_A7K8f.seq check
>D04925A7_A7K8_2_EGFR-F5_G06_21_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN NNGGNNGGTG GGGGCCCTCC TCTTGCTGCT GGTGGTGGCC
   61 CTGGGGNNCG GCCTCTTCAT GCGAAGGCGC CACATCGTTC GGAAGCGCAC GCTGCGGAGG
  121 CTGCTGCAGG AGAGGGAGCT TGTGGAGCCT CTTACACCCA GTGGAGAAGC TCCCAACCAA
  181 GCTCTCTTGA GGATCTTGAA GGAAACTGAA TTCAAAAAGA TCAAAGTGCT GGGCTCCGGT
  241 GCGTTCGGCA CGGTGTATAA GGGACTCTGG ATCCCAGAAG GTGAGAAAGT TAAAATTCCC
  301 GTCGCTATCA AGGAATTAAG AGAAGCAACA TCTCCGAAAG CCAACAAGGA AATCCTCGAT
  361 GAAGCCTACG TGATGGCCAG CGTGGACAAC CCCCACGTGT GCCGCCTGCT GGGCATCTGC
  421 CTCACCTCCA CCGTGCAGCT CATCATGCAG CTCATGCCCT TCGGCTGCCT CCTGGACTAT
  481 GTCCGGGAAC ACAAAGACAA TATTGGCTCC CAGTACCTGC TCAACTGGTG TGTGCAGATC
  541 GCAAAGGGCA TGAACTACTT GGAGGACCGT CGCTTGGTGC ACCGCGACCT GGCAGCCAGG
  601 AACGTACTGG TGAAAACACC GCAGCATGTC AAGATCACAG ATTTTGGGCG GGCCAAACTG
  661 CTGGGTGCGG AAGAGAAAGA ATACCATGCA GAANGAGGCA AAGTGCCTAT CAAGTGGATG
  721 GCATTGGAAT CAATTTTACA CAGAATCTAT ACCCACCAGA NTGATGTCTG GANCTACNGG
  781 GTGANCGTTT GGGANTTGAN GANCTTNNGA TCCNAGCCAT ATGACGGAAT CCCNGCCAGC
  841 NANNTCTCCT CCNTCCNGGA NAAAGGANAA CGNCTCCNNC ANCCACCCNT ATGNACCNTC
  901 NNNGTCNANN TNATCANGGN NNANNNCTNN NNGANANNNN CANANANNCG NCNNANNNNN
961 NNNNN
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]